The first, formal revision of specific guidelines, known as RECIST, used by clinicians to measure tumour size and response to treatment, has been published today (Tuesday 20 January) in a special issue of the European Journal of Cancer (the official journal of ECCO - the European CanCer Organisation) [1]. Complete news at...
PREVIEW: Please join us for lunch and a preview on 27 January 2009, 1 - 2.30pm, Breast Cancer Haven, Effie Road, London, SW6 1TB Speakers: Caroline Hoffman, Clinical Director, Breast Cancer Haven. Dr Andrew Vallance-Owen, Bupa's Group Medical Director. Professor Dudley Sinnett, Consultant Breast Surgeon. Complete news at...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a drug for treating stage IV malignant melanoma that can increase median overall survival when compared with standard of care dacarbazine (Bedford Laboratories' DTIC-Dome, generics) would earn a higher patient share in the U.S. (60 percent) than in Europe (40 percent), according to surveyed U.S. and European oncologists. Complete news at...
Dr Sarah Cant, Policy Manager at Breakthrough Breast Cancer, says: "This research, whilst interesting, is only relevant to a very small proportion of women - those with a strong family history but without a BRCA gene fault. The researchers suggest that these women could benefit from extra breast screening and taking tamoxifen to reduce their breast cancer risk. However, tamoxifen is not currently licensed for this use in the UK. Complete news at...
Researchers long ago established a link between inflammation, cancer and the compound nitric oxide, which may be produced when the immune system responds to bacterial infections, including those of the colon. However, the exact nature of the relationship was unknown - until now. Complete news at...
Researchers at Mayo Clinic have found that the experimental drug they are testing to treat a deadly form of thyroid cancer turns on a powerful tumor suppressor capable of halting cell growth. Few other cancer drugs have this property, they say. In the Feb. 15 issue of Cancer Research (available online Jan. 20), they report that RS5444, being tested in a Phase 1/2 clinical trial to treat anaplastic thyroid cancer, might be useful for treating other cancers. Complete news at...
A chemical commonly used in the manufacture of rubber products may cause cancer in workers regularly exposed to it, suggests research published ahead of print in Occupational and Environmental Medicine. The researchers base their findings on higher than expected rates of certain cancers, and deaths from the disease, among men working at a rubber chemicals plant in North Wales. Complete news at...
Tuesday, January 20, 2009
Monday, January 19, 2009
Two Thirds Of Doctors Against Moving Antibiotic Trimethoprim To OTC
Two Thirds Of Doctors Against Moving Antibiotic Trimethoprim To OTC
Almost two thirds of doctors are opposed to the Medicines and Healthcare products Regulatory Agency (MHRA) plans to make the antibiotic trimethoprim available over the counter, according to a survey of readers of an influential journal.
Research!America Selects Ambassador To Join Distinguished Health Experts In Seeking Greater US Investment In Global Health
Research!America honored Dr. Keith C. Norris, the executive vice president for Research and Health Affairs at Charles Drew University of Medicine and Science, by naming him an "ambassador" for the nonprofit organization's Paul G. Rogers Society for Global Health Research. The Rogers Society, named for the late Florida Congressman Paul G. Rogers (1921-2008), a champion for health research and Research!America chair emeritus, advocates for greater U.S.
King's Winning Fight Against Clostridium Difficile
Figures published today by the Health Protection Agency (HPA) show that King's College Hospital has seen a major reduction in the number of cases of Clostridium difficile reported at the Trust. During the most recent quarter for which figures are available (July to September 2008), there were 35 cases of Clostridium difficile recorded at King's. This is a major reduction on the number of cases reported between April and June 2008, which was 99.
Cobalis Corp Gets Federal Court Approval To Launch Its Flagship Anti-Allergy Product PreHistin™
Cobalis Corp. (OTC:CLSC), a pharmaceutical biotech Company specializing in the development of anti-allergy medications, announced the planned marketing launch of the flagship anti-allergy product PreHistin™ after approval in Federal Court in Santa Ana, CA on Jan. 13, 2009. The launch of PreHistin™ is scheduled for February 2009, and will enable the company to be discharged from Chapter 11. Cobalis Corp.
For Cold And Flu Season, The Wrong Prescription Is Free Antibiotics
With an epidemic of antibiotic-resistant infections growing, experts are warning grocery-store pharmacies that antibiotics giveaways are an unhealthy promotional gimmick. If grocery stores want to help customers and save them money during cold and flu season, the Infectious Diseases Society of America (IDSA) says, they should offer free influenza vaccinations instead. Giant, Stop & Shop, and other grocery stores have recently begun offering free antibiotics at their pharmacies.
ViraCor Laboratories Launches Fastest Available Cytomegalovirus Antiviral Resistance Test
ViraCor Laboratories, the leader in molecular diagnostic testing for infectious diseases, announced the launch of a new cytomegalovirus (CMV) antiviral resistance test that provides diagnosis days faster than other tests on the market. Developed in ViraCor's laboratories, the molecular test accurately detects key genetic mutations associated with antiviral resistance in CMV in three days or less. Turnaround time on most CMV antiviral resistance tests is up to two weeks.
Almost two thirds of doctors are opposed to the Medicines and Healthcare products Regulatory Agency (MHRA) plans to make the antibiotic trimethoprim available over the counter, according to a survey of readers of an influential journal.
Research!America Selects Ambassador To Join Distinguished Health Experts In Seeking Greater US Investment In Global Health
Research!America honored Dr. Keith C. Norris, the executive vice president for Research and Health Affairs at Charles Drew University of Medicine and Science, by naming him an "ambassador" for the nonprofit organization's Paul G. Rogers Society for Global Health Research. The Rogers Society, named for the late Florida Congressman Paul G. Rogers (1921-2008), a champion for health research and Research!America chair emeritus, advocates for greater U.S.
King's Winning Fight Against Clostridium Difficile
Figures published today by the Health Protection Agency (HPA) show that King's College Hospital has seen a major reduction in the number of cases of Clostridium difficile reported at the Trust. During the most recent quarter for which figures are available (July to September 2008), there were 35 cases of Clostridium difficile recorded at King's. This is a major reduction on the number of cases reported between April and June 2008, which was 99.
Cobalis Corp Gets Federal Court Approval To Launch Its Flagship Anti-Allergy Product PreHistin™
Cobalis Corp. (OTC:CLSC), a pharmaceutical biotech Company specializing in the development of anti-allergy medications, announced the planned marketing launch of the flagship anti-allergy product PreHistin™ after approval in Federal Court in Santa Ana, CA on Jan. 13, 2009. The launch of PreHistin™ is scheduled for February 2009, and will enable the company to be discharged from Chapter 11. Cobalis Corp.
For Cold And Flu Season, The Wrong Prescription Is Free Antibiotics
With an epidemic of antibiotic-resistant infections growing, experts are warning grocery-store pharmacies that antibiotics giveaways are an unhealthy promotional gimmick. If grocery stores want to help customers and save them money during cold and flu season, the Infectious Diseases Society of America (IDSA) says, they should offer free influenza vaccinations instead. Giant, Stop & Shop, and other grocery stores have recently begun offering free antibiotics at their pharmacies.
ViraCor Laboratories Launches Fastest Available Cytomegalovirus Antiviral Resistance Test
ViraCor Laboratories, the leader in molecular diagnostic testing for infectious diseases, announced the launch of a new cytomegalovirus (CMV) antiviral resistance test that provides diagnosis days faster than other tests on the market. Developed in ViraCor's laboratories, the molecular test accurately detects key genetic mutations associated with antiviral resistance in CMV in three days or less. Turnaround time on most CMV antiviral resistance tests is up to two weeks.
Cardioprotective Effects Beyond Blood Pressure Reduction Provided By Salt Reduction
A study published in the February 2009 issue of the American Journal of Clinical Nutrition shows that salt reduction may offer cardioprotective effects beyond blood pressure reduction. The study was led by Kacie Dickinson of Flinders University, South Australia. "Reducing your salt intake provides more benefit than a decrease in blood pressure," said ASN Spokesperson Mary Ann Johnson, PhD. Continue reading ...
Challenging heart rhythm disorders, or arrhythmias, require electrophysiology (EP) technologies to pinpoint and ultimately fix problem areas within the heart's electrical circuitry during an interventional procedure. As EP procedure volume increases worldwide, clinicians are requesting intuitive, advanced tools to help shorten procedure times and gain detailed visualizations for interventions. Continue reading ...
Challenging heart rhythm disorders, or arrhythmias, require electrophysiology (EP) technologies to pinpoint and ultimately fix problem areas within the heart's electrical circuitry during an interventional procedure. As EP procedure volume increases worldwide, clinicians are requesting intuitive, advanced tools to help shorten procedure times and gain detailed visualizations for interventions. Continue reading ...
Subscribe to:
Posts (Atom)
